Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences develops neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. Its news commonly centers on EB-003, a lead candidate from the EVM301 Series designed to promote neuroplasticity without hallucinogenic effects and to modulate 5-HT2A and 5-HT1B receptors. Company updates also discuss preclinical models tied to PTSD, depression, anxiety and related neuropsychiatric conditions.
Recurring announcements include intellectual-property activity for the EVM301 and EVM401 Series, trademark registrations, corporate and financial results, and capital actions involving common stock, pre-funded warrants and other warrants. Enveric also reports business-development and conference activity around non-hallucinogenic and psychedelic-inspired therapeutic approaches.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing therapeutics for anxiety, depression, and addiction, announced participation in the Benzinga Psychedelics Capital Conference on April 13, 2023. CEO Joseph Tucker will engage in a fireside chat at 10:30 a.m. ET and a panel titled NextGen Psychedelics at 3:20 p.m. ET. The event will take place at the Fontainebleau Miami Beach.
Dr. Tucker aims to showcase Enveric's clinical development strategy, including the upcoming Phase 1 study of lead candidate EB-373 in Australia.
Enveric Biosciences (NASDAQ: ENVB) announces significant developments in their pipeline targeting mental health disorders. They've nominated EB-373 as the lead candidate for treating anxiety disorders, advancing from their EVM201 Series. A Phase 1 clinical trial is set to start in Q4 2023 in Australia, utilizing the contract research organization, Avance Clinical. Financially, the company reported a $19.3 million net loss for 2022, an improvement from the previous year's $48.8 million. The company also plans a spin-off of its cannabinoid pipeline to Akos Biosciences, Inc.. Overall, Enveric is poised for an active 2023, targeting innovations in mental health therapies.
Enveric Biosciences (NASDAQ: ENVB) announced plans to launch a first-in-human clinical trial for its lead candidate, EB-373, in Q4 2023. This proprietary psilocin prodrug targets anxiety disorders and has been designated as a New Chemical Entity by Australia’s Therapeutic Goods Administration. Enveric has partnered with Avance Clinical, an experienced contract research organization, to manage the trial, which will evaluate EB-373's safety and tolerability through a multi-cohort, dose-ascending approach. The company aims to innovate treatment options for anxiety, capitalizing on its Psybrary drug discovery platform.
Enveric Biosciences (NASDAQ: ENVB) announced groundbreaking research detailing the isolation of a novel indolethylamine N-methyltransferase from the cane toad (Rhinella marina). This discovery enables a new bioproduction platform for developing psychedelic-inspired drug candidates aimed at treating psychiatric disorders like anxiety and depression. The research was conducted by the University of Calgary and led by Dr. Peter Facchini. Enveric aims to begin human clinical trials for their lead product, EB-373, for anxiety treatment, reflecting their commitment to innovate in mental health therapeutics.